Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity
Maria Elena Maccari,Martin Wolkewitz,Charlotte Schwab,Tiziana Lorenzini,Jennifer W Leiding,Nathalie Aladjdi,Hassan Abolhassani,Wadih Abou-Chahla,Alessandro Aiuti,Saba Azarnoush,Safa Baris,Vincent Barlogis,Federica Barzaghi,Ulrich Baumann,Marketa Bloomfield,Nadezda Bohynikova,Damien Bodet,David Boutboul,Giorgia Bucciol,Matthew S Buckland,Siobhan O Burns,Caterina Cancrini,Pascal Cathébras,Marina Cavazzana,Morgane Cheminant,Matteo Chinello,Peter Ciznar,Tanya I Coulter,Maud D'Aveni,Olov Ekwall,Zelimir Eric,Efrem Eren,Anders Fasth,Pierre Frange,Benjamin Fournier,Marina Garcia-Prat,Martine Gardembas,Christoph Geier,Sujal Ghosh,Vera Goda,Lennart Hammarström,Fabian Hauck,Maximilian Heeg,Edyta Heropolitanska-Pliszka,Anna Hilfanova,Stephen Jolles,Elif Karakoc-Aydiner,Gerhard R Kindle,Ayca Kiykim,Christian Klemann,Patra Koletsi,Sylwia Koltan,Irina Kondratenko,Julia Körholz,Renate Krüger,Eric Jeziorski,Romain Levy,Guillaume Le Guenno,Guillaume Lefevre,Vassilios Lougaris,Antonio Marzollo,Nizar Mahlaoui,Marion Malphettes,Andrea Meinhardt,Etienne Merlin,Isabelle Meyts,Tomas Milota,Fernando Moreira,Despina Moshous,Anna Mukhina,Olaf Neth,Jennifer Neubert,Benedicte Neven,Alexandra Nieters,Raphaele Nove-Josserand,Eric Oksenhendler,Ahmet Ozen,Peter Olbrich,Antoinette Perlat,Malgorzata Pac,Jana Pachlopnik Schmid,Lucia Pacillo,Alba Parra-Martinez,Olga Paschenko,Isabelle Pellier,Asena Pinar Sefer,Alessandro Plebani,Dominique Plantaz,Seraina Prader,Loic Raffray,Henrike Ritterbusch,Jacques G Riviere,Beatrice Rivalta,Stephan Rusch,Inga Sakovich,Sinisa Savic,Raphael Scheible,Nicolas Schleinitz,Catharina Schuetz,Ansgar Schulz,Anna Sediva,Michaela Semeraro,Svetlana O Sharapova,Anna Shcherbina,Mary A Slatter,Georgios Sogkas,Pere Soler-Palacin,Carsten Speckmann,Jean-Louis Stephan,Felipe Suarez,Alberto Tommasini,Johannes Trück,Annette Uhlmann,Koen J van Aerde,Joris van Montfrans,Horst von Bernuth,Klaus Warnatz,Tony Williams,Austen J J Worth,Winnie Ip,Capucine Picard,Emilie Catherinot,Zohreh Nademi,Bodo Grimbacher,Lisa R Forbes Satter,Sven Kracker,Anita Chandra,Alison M Condliffe,Stephan Ehl,European Society for Immunodeficiencies Registry Working Party,Markus G Seidel,Mikko R J Seppänen,Andrew Gennery,Maria G Kanariou,Sofia Tantou,Sofia Grigoriadou,Gabriella Cericola,Leif G Hanitsch,Carmen Scheibenbogen,Eva O Hlaváčková,Gergely Krivan,Frances K McGuire,Timothy Ronan Leahy,John David M Edgar,Shahrzad Bakhtiar,Peter Bader,Geraldine Blanchard Rohner,Filomeen Haerynck,Karlien Claes,Kai Lehmberg,Ingo Müller,Susan Farmand,Maria Fasshauer,Dagmar Graf,Joao Farela Neves,Larysa Kostyuchenko,Luis Ignacio Gonzalez-Granado,Miloš Jeseňák,Maria Carrabba,Giovanna Fabio,Claudio Pignata,Giuliana Giardino,Ilknur Kökçü Karadağ,Alişan Yıldıran,Gonca Hancioglu,Pavlína Králíčková,Sandra Steinmann,Barbara Maria Pietrucha,Michael Gernert,Maarja Soomann,Torsten Witte,Adam Markocsy,Beata Wolska-Kusnierz,Philippe Randrianomenjanahary,Jérémie Rouger,Stavroula Kostaridou,Dariia V Zabara,Yulia A Rodina,Oksana A Shvets
DOI: https://doi.org/10.1016/j.jaci.2023.06.015
Abstract:Background: Activated phosphoinositide-3-kinase δ syndrome (APDS) is an inborn error of immunity (IEI) with infection susceptibility and immune dysregulation, clinically overlapping with other conditions. Management depends on disease evolution, but predictors of severe disease are lacking. Objectives: This study sought to report the extended spectrum of disease manifestations in APDS1 versus APDS2; compare these to CTLA4 deficiency, NFKB1 deficiency, and STAT3 gain-of-function (GOF) disease; and identify predictors of severity in APDS. Methods: Data was collected from the ESID (European Society for Immunodeficiencies)-APDS registry and was compared with published cohorts of the other IEIs. Results: The analysis of 170 patients with APDS outlines high penetrance and early onset of APDS compared to the other IEIs. The large clinical heterogeneity even in individuals with the same PIK3CD variant E1021K illustrates how poorly the genotype predicts the disease phenotype and course. The high clinical overlap between APDS and the other investigated IEIs suggests relevant pathophysiological convergence of the affected pathways. Preferentially affected organ systems indicate specific pathophysiology: bronchiectasis is typical of APDS1; interstitial lung disease and enteropathy are more common in STAT3 GOF and CTLA4 deficiency. Endocrinopathies are most frequent in STAT3 GOF, but growth impairment is also common, particularly in APDS2. Early clinical presentation is a risk factor for severe disease in APDS. Conclusions: APDS illustrates how a single genetic variant can result in a diverse autoimmune-lymphoproliferative phenotype. Overlap with other IEIs is substantial. Some specific features distinguish APDS1 from APDS2. Early onset is a risk factor for severe disease course calling for specific treatment studies in younger patients.